Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Screening for ovariecancer hos ældre patienter (PLCO Screening Trial)

10. november 2026 opdateret af: National Cancer Institute (NCI)

Forsøg med screening af prostata-, lunge-, kolorektal- og ovariekræft (PLCO).

This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for ovarian cancer. The ovarian cancer screening tests are part of a trial that addresses the screening of four cancer sites, each with their own results record: prostate (NCT00002540), lung (NCT01696968), colorectal (NCT01696981), and ovarian (NCT01696994).

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

PRIMARY OBJECTIVES:

I. To determine whether screening with CA125 and transvaginal ultrasound (TVU) can reduce mortality from ovarian cancer in women aged 55-74 at entry.

SECONDARY OBJECTIVES:

I. To assess screening variables, other than mortality, for each of the interventions including sensitivity, specificity, and positive predictive value.

II. To assess the incidence, stage, and survival of cancer cases. III. To investigate the mortality predictive value of biologic and/or prognostic characterizations of tumor tissue as intermediate endpoints.

IV. To conduct biomolecular and genetic research into factors associated with cancer carcinogenesis and promotion, as well as the early detection of these factors.

OUTLINE: Participants in the overall PLCO study are stratified by screening center, gender, and age (55-59 vs 60-64 vs 65-69 vs 70-74). Participants are randomized to 1 of 2 arms (control vs screening).

ARM I (Control): Participants receive standard medical care. Participants complete a Diet History Questionnaire (DHQ) at baseline.

ARM II (Ovarian Screening): Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an ovarian palpation exam (OVR, discontinued in December 1998) and TVU at baseline and annually for 3 years. A scheduling and tracking procedure is implemented to ensure regular attendance at repeat screens for participants screened negative or for those who are designated suspicious or positive at screening but for whom subsequent diagnostic procedures do not reveal ovarian cancer (follow-up diagnostic procedures are through their own medical care environment). Participants diagnosed with ovarian cancer via a screening test are referred for treatment in accordance with current accepted practice for appropriate stage of disease, patient age, and medical condition; a procedure is provided for contact with qualified medical personnel to insure appropriate therapy.

Participants complete a Dietary Questionnaire (DQX) at baseline and DHQ at year 3. An Annual Study Update (ADU) (previously referred to as the Periodic Survey of Health [PSH] questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.

After completion of screening, participants are followed up for at least 13 years.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

78216

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Maryland
      • Bethesda, Maryland, Forenede Stater, 20892
        • National Institutes of Health Clinical Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

55 år til 74 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Exclusion Criteria:

  • Women who at the time of randomization are less than 55 or greater than or equal to 75 years of age

  • Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer

  • Individuals with known prior cancer of the colon, rectum, lung, or ovary

    • This includes primary or metastatic PLCO cancers
  • Individuals with previous surgical removal of the entire colon or one lung

    • Until October 1996, women with previous surgical removal of both ovaries were excluded from the trial. In order to increase the enrollment of women into the trial, beginning in October 1996, these women were no longer excluded for this reason.
  • Individuals who are participating in another cancer screening or cancer primary prevention trial

  • Prior to April 1, 1999 women were excluded from the trial if they were currently taking or had taken Tamoxifen or Evista\Raloxifene in the past 6 months. As of April 1999 based on a decision from the PLCO Ovary Subcommittee, women who have or are currently taking Tamoxifen or Evista\Raloxifene are not excluded from participation.

  • Individuals who are unwilling or unable to sign the informed consent form

  • Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past three years

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Screening
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Ingen indgriben: Control

Participants receive standard medical care. Participants complete a DHQ at baseline.

Aktiv komparator: Ovarian Screening

Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.

Correlative studies

Undergo questionnaire assessments

Undergo TVU

Andre navne:
  • Ultralyd
  • 2-dimensionel gråtone-ultralydsbilleddannelse
  • 2-dimensionel ultralydsbilleddannelse
  • 2D-US
  • Ultralydstest
  • Ultralyd, medicinsk
  • OS

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ovarian Cancer Deaths (Including Primary Peritoneal and Fallopian Tube Cancers)
Tidsramme: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Ovarian Cancer Death Rates (Including Primary Peritoneal and Fallopian Tube Cancers)
Tidsramme: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Deaths From All Causes
Tidsramme: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Deaths from all causes were compared between the ovarian cancer screening arm and the usual care arm.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Death Rates From All Causes
Tidsramme: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Deaths from all causes were compared between the ovarian cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Ovarian Cancer Incidence (Including Primary Peritoneal and Fallopian Tube Cancers)
Tidsramme: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Ovarian cancer diagnoses confirmed by medical record abstraction.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Ovarian Cancer Incidence Rates (Including Primary Peritoneal and Fallopian Tube Cancers).
Tidsramme: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Ovarian cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as ovarian cancer diagnoses divided by person years at risk for ovarian cancer.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test
Tidsramme: One year from screening examination

Number of positive screens with complications

One year from screening examination
T0 (Baseline) CA-125 Screening Results
Tidsramme: T0 (at study entry)

Cancer Antigen 125 (CA-125) result.

T0 (at study entry)
T0 (Baseline) TVU Screening Results
Tidsramme: T0 (at study entry)

Transvaginal Ultrasound (TVU) result.

T0 (at study entry)
T1 CA-125 Screening Results
Tidsramme: T1 (one year after entry)

Cancer Antigen 125 (CA-125) result.

T1 (one year after entry)
T1 TVU Screening Results
Tidsramme: T1 (one year after entry)

Transvaginal Ultrasound (TVU) result.

T1 (one year after entry)
T2 CA-125 Screening Results
Tidsramme: T2 (two years after entry)

Cancer Antigen 125 (CA-125) result.

T2 (two years after entry)
T2 TVU Screening Results
Tidsramme: T2 (one year after entry)

Transvaginal Ultrasound (TVU) result.

T2 (one year after entry)
T3 CA-125 Screening Results
Tidsramme: T3 (three years after entry)

Cancer Antigen 125 (CA-125) result.

T3 (three years after entry)
T3 TVU Screening Results
Tidsramme: T3 (three years after entry)

Transvaginal Ultrasound (TVU) result.

T3 (three years after entry)
T4 CA-125 Screening Results
Tidsramme: T4 (four years after entry)

Cancer Antigen 125 (CA-125) result.

T4 (four years after entry)
T5 CA-125 Screening Results
Tidsramme: T5 (five years after entry)

Cancer Antigen 125 (CA-125) result.

T5 (five years after entry)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Christine D Berg, National Cancer Institute (NCI)

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

16. november 1993

Primær færdiggørelse (Faktiske)

21. maj 2012

Studieafslutning (Anslået)

30. juni 2027

Datoer for studieregistrering

Først indsendt

28. september 2012

Først indsendt, der opfyldte QC-kriterier

1. oktober 2012

Først opslået (Anslået)

2. oktober 2012

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

13. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • NCI-2012-01758
  • CDR0000078532
  • NCI-P93-0050
  • PLCO-1
  • NCI-2012-01758 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
  • PLCO-Ovarian (Anden identifikator: National Cancer Institute)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .